ClinicalTrials.gg
RecruitingNCT07168512Updated Sep 18, 2026

Effect of Myofascial Release Technique Alone or Combined With Exercises on Cervical Cobb Angle, Sleep Quality, and Psychological Factors in Patients With Cervicogenic Headache

An interventional study of Exercises (Endurance and strengthening) and Myofascial release technique in Effect of Physiotherapy on Cobb Angle in Patients With Cervicogenic Headache, sponsored by Al-Azhar University. Recruiting at 3 sites in Palestinian Territories. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

This study will investigate whether myofascial release therapy alone or in combination with therapeutic exercises can improve cervical spine alignment, measured by cervical Cobb angle on X-ray, in patients with cervicogenic headache. The research will also examine potential effects on sleep quality and psychological factors."

02

Conditions studied

  • Effect of Physiotherapy on Cobb Angle in Patients With Cervicogenic Headache

Keywords

  • cobb angle
  • sleep
  • cervicogenic headache
  • exercise
  • myofascial release
03

In context

Post-Traumatic Headache

192 studies on the registry are indexed under Post-Traumatic Headache; 54 are open to participants now.

This study's planned enrollment of 100 is above the median of 44 across 169 interventional studies indexed under Post-Traumatic Headache.

Browse Post-Traumatic Headache studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20-55 years.
  • Clinical diagnosis of cervicogenic headache according to International Classification of Headache Disorders (ICHD-3) criteria (headache attributed to cervical disorder).

Exclusion criteria

Exclusion Criteria:

  • History of major cervical spine pathology such as fracture, dislocation, congenital malformation, tumor, infection, or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis).
  • Previous cervical spine surgery or fusion at any level.
  • Red flag symptoms indicating serious pathology (e.g., progressive neurological deficit, unexplained weight loss, fever, history of cancer).
  • Systemic or neurological disorders that may affect neck function or headache (e.g., multiple sclerosis, Parkinson's disease).
  • Severe osteoporosis or metabolic bone disease that contraindicates cervical X-ray imaging.
  • Vascular disorders such as vertebrobasilar insufficiency or carotid artery disease.
  • Pregnancy or breastfeeding (due to radiation exposure during cervical radiography).
  • Unstable psychiatric conditions (e.g., severe depression, psychosis) that may interfere with participation or adherence.
  • Recent physiotherapy or manual therapy targeting the cervical region within the past 6 weeks, or planned during the study outside the protocol.
  • Use of botulinum toxin or injections to the neck or head region in the past 6 months.
  • to manual therapy or exercise (e.g., acute cervical disc herniation, severe myelopathy, unstable cardiovascular disease).
  • Inability to understand study procedures, comply with treatment sessions, or provide .
  • Symptoms of migraine, tension-type headache (TTH), or any other headache apart from cervicogenic headache.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    One group will receive exercises

    The intervention will include targeted neck strengthening and endurance exercises combined with the application of hot packs

    Other: Exercises (Endurance and strengthening)

  • Experimental
    Exercises and Myofascial release technique

    The intervention will include targeted neck strengthening and endurance exercises combined with the application of hot packs in addition to myofasical release technique

    Other: Exercises (Endurance and strengthening) · Other: Myofascial release technique

  • No intervention
    Control

    control ; only advices

Interventions

  • OtherExercises (Endurance and strengthening)

    Neck Strengthening and Endurance Exercises with Hot Packs Preparation: A moist hot pack will be applied for 10-15 minutes to the cervical region before exercise to reduce stiffness and enhance tissue extensibility. Exercise program: Deep cervical flexor training: Chin tucks in supine and sitting, progressing to sustained isometric holds. Extensor and scapular stabilizer training: Prone head lifts and shoulder retraction exercises with light resistance. Endurance training: Low-load, high-repetition exercises focusing on maintaining cervical posture against gravity. Progression: Intensity and duration will gradually increase, emphasizing endurance over maximal strength to correct postural deficits. Frequency: 40 minutes per session, 3 times per week for 6 weeks Rationale: The combined use of heat and targeted exercises improves neuromuscular control, enhances cervical stability, and supports better cervical curvature correction. Myofascial Release Technique

  • OtherMyofascial release technique

    Myofascial Release Technique Target areas: Suboccipital muscles, upper trapezius, levator scapulae, and deep cervical fascia. Method: A physiotherapist will perform gentle, sustained manual pressure and low-load, long-duration stretching on restricted cervical and upper thoracic fascia to reduce tension and improve soft tissue mobility. Duration and frequency: Each session will include 30'to 50 minutes of myofascial release, delivered 3 times per week for the study period for 6 weeks. Rationale: This technique aims to decrease myofascial restrictions contributing to abnormal cervical alignment and pain, thereby facilitating improved posture and muscle activation.

06

What researchers measure

Primary outcomes

  1. Cervical cobb angle

    Time frame: pre and post (6 weeks)

  2. Cobb angle of cervical spine assessed by X Ray (Lateral)

    Landmarks \& angle construction (C2-C7 Cobb) Draw a line along the inferior endplate of C2. Draw a line along the inferior endplate of C7. Erect perpendiculars to each line and measure the angle at their intersection (alternatively, measure the acute angle between the two endplate lines and subtract from 180°). Record the angle in degrees of lordosis (greater positive values = greater lordosis). Note the sign convention in your CRF and keep it consistent pre/post. Normal value is between 20\_40

    Time frame: pre , and 8 weeks post physiotherapy intervention

  3. Hospital Anxiety and depression scale

    The Hospital Anxiety and Depression Scale (HADS) is a validated self-report screening tool developed to assess levels of anxiety and depression in patients, particularly in non-psychiatric hospital settings. It contains 14 items divided into two subscales: seven items for anxiety (HADS-A) and seven for depression (HADS-D). Each item is scored on a 4-point Likert scale ranging from 0 to 3, giving a maximum score of 21 for each subscale. Higher scores indicate greater symptom severity. Scores of 0-7 are generally considered normal, 8-10 suggest borderline (possible) anxiety or depression, and 11-21 indicate clinically significant levels. The HADS is widely used in clinical and research contexts due to its brevity, ease of administration, and ability to distinguish between anxiety and depression symptoms without being confounded by physical illness.

    Time frame: pre and 8 weeks post physiotherapy interventions

Secondary outcomes

  1. sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire designed to assess sleep quality and disturbances over a one-month period. It consists of 19 items grouped into seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 (no difficulty) to 3 (severe difficulty), and the component scores are summed to yield a global score ranging from 0 to 21. A higher score indicates poorer sleep quality, with a global score greater than 5 commonly used to differentiate between good and poor sleepers. The PSQI is valued for its reliability, validity, and practicality in both clinical and research settings for evaluating sleep problems across diverse populations.

    Time frame: pre, and 8 weeks post physiotherapy

  2. neck disability

    The Neck Disability Index (NDI) is a self-administered questionnaire designed to measure a patient's level of neck pain-related disability. It consists of 10 items covering domains such as pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation. Each item is scored on a 6-point scale ranging from 0 (no disability) to 5 (complete disability), resulting in a total possible score of 50. The raw score is often expressed as a percentage by multiplying by two. Higher scores indicate greater disability, with common interpretation ranges being: 0-4 (no disability), 5-14 (mild), 15-24 (moderate), 25-34 (severe), and ≥35 (complete disability). The NDI is one of the most widely used tools for assessing functional status in patients with neck pain, demonstrating strong reliability, validity, and responsiveness to clinical change.

    Time frame: pre and 8 weeks post physiotherapy interventions

07

Study locations

1 of 3 sites recruiting
  • Naser Medical Complex
    Gaza, Gaza Strip, Palestinian Territories
    Not yet recruiting
  • Ministry of Health
    Gaza, Palestinian Territories
    Not yet recruiting
  • Naser medical Complex, Al shifa hospital
    Gaza, Palestinian Territories
    Recruiting
08

References and documents

Publications

  • Cervical Cobb angle, sleep quality and psychological factors in patients with chronic neck pain with and without cervicogenic headache

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 89 non-industry interventional studies with no phase under Post-Traumatic Headache, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 15 months is above that.

Counting every sponsor, half of 90 studies reached it within 12 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 11, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Dec 12, 2026
CompletionEst.
Dec 20, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07168512
Responsible party
Mosab ALdabbas (mosab aldabbas, Al-Azhar University) — Principal investigator
First posted
Sep 11, 2025
Start date
Sep 4, 2025
Primary completion
Dec 12, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Sep 18, 2026

Study contacts

MOSAB ALDABBAS
Contact
mosab.m.aldabbas@gmail.com
00972597451222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion